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Over the past few decades, there has been an increase in the number of reports about newly recognized (atypical or unusual)
manifestations of Graves’ disease (GD), that are related to various body systems. One of these manifestations is sometimes the
main presenting feature of GD. Some of the atypical manifestations are speciﬁcally related to GD, while others are also similarly
seen in patients with other forms of hyperthyroidism. Lack of knowledge of the association between these ﬁndings and GD may
lead to delay in diagnosis, misdiagnosis, or unnecessary investigations. The atypical clinical presentations of GD include anemia,
vomiting,jaundice,andrightheartfailure.Thereisonetypeofanemiathatisnotexplainedbyanyoftheknownetiologicalfactors
and responds well to hyperthyroidism treatment. This type of anemia resembles anemia of chronic disease and may be termed GD
anemia. Other forms of anemia that are associated with GD include pernicious anemia, iron deﬁciency anemia of celiac disease,
and autoimmune hemolytic anemia. Vomiting has been reported as a presenting feature of Graves’ disease. Some cases had the
typical ﬁndings of hyperthyroidism initially masked, and the vomiting did not improve until hyperthyroidism has been detected
andtreated.Hyperthyroidismmaypresentwithjaundice,andontheotherhand,deepjaundicemaydevelopwiththeonsetofovert
hyperthyroidism in previously compensated chronic liver disease patients. Pulmonary hypertension is reported to be associated
with GD and to respond to its treatment. GD-related pulmonary hypertension may be so severe to produce isolated right-sided
heart failure that is occasionally found as the presenting manifestation of GD.
1.Introduction
Graves’ disease (GD) accounts for up to 80% of hyperthy-
roidism cases and is estimated to aﬀect 0.5% of the popula-
tion [1]. It usually presents with the common well- known
symptoms and signs (goiter, ophthalmopathy, weight loss,
nervousness, tremors, palpitations, sweating, etc.) which are
the distinctive features of the disease (Table 1). We can
observe another group of manifestations, such as periodic
paralysis, apathy, or psychosis, which are less common and
less distinctive despite being well documented in relation to
GD (Table 1). Over the past few decades, there has been an
increase in the number of reports about newly recognized
(atypicalorunusual)manifestationsofhyperthyroidismthat
are related to various body systems and may create a wide
range of diﬀerential diagnosis [2, 3]. Most of these atypical
manifestations are mainly reported in patients with GD
(Table 1), either due to a speciﬁc relation to the autoimmune
thyroid disorder, or because GD accounts for the majority
of hyperthyroidism cases. Occasionally, one of the atypical
manifestations is the main presenting feature of GD [2].
Lack of knowledge of the association between these ﬁndings
and GD may lead to delay in diagnosis, misdiagnosis, or
unnecessary investigations.
The atypical manifestations of GD represent a wide
spectrum of clinical and laboratory ﬁndings, and in this
reviewwewillfocusontheclinicalpartofthatspectrum.For
example, while hematological manifestations of GD include
thrombocytopenia, leucopenia, anemia, and pancytopenia;
we will discuss anemia as the clinical presenting feature.
Other atypical clinical presentations of GD that will be
discussedherearevomiting,jaundice,andrightheartfailure.
These manifestations can be attributed to a wide variety
of hematological, gastrointestinal, and cardiopulmonary2 Journal of Thyroid Research
Table 1: Manifestations of Graves’ disease (GD).
Well recognized/common Recognized/Less common Unusual/atypical (estimated prevalence in GD patients)
Weight loss Agitation/psychosis Jaundice (mild hyperbilirubinemia in up to 30%)
Anxiety/nervousness Apathy/depression Vomiting (up to 44%)
Tremors Confusion/delirium A n e m i a( u pt o3 3 % )
Goiter Myopathy Pancytopenia
Tachyarrhythmia Paraparesis or quadriparesis Leukopenia/thrombocytopenia
Breathlessness Abnormal liver function tests Heart block
Left ventricular failure Myocardial infarction
Increased bowel
movements
Pulmonary hypertension (up to 43%)
Sweating Right heart failure
Heat intolerance Angioedema
Staring gaze/exophthalmos Erythema annulare centrifugum
causes, and each of them represents a very common clinical
condition.
2. Anemia
Anemia is not uncommonly found in association with GD.
It has been found in 33% of GD patients [4], and was
a presenting manifestation in up to 34% of cases with
hyperthyroidism [5]. It is somewhat challenging to face
anemia as the presenting manifestation of GD, especially
when the typical clinical features of hyperthyroidism are
subtle or overlooked. Regardless of the incidental association
of GD with other forms of anemia (e.g., iron deﬁciency
anemia, thalassemia, etc.), there are speciﬁc types of anemia
that are directly or indirectly related to GD (Table 2). As an
autoimmune disease, GD was found to be associated with
other autoimmune diseases that include pernicious anemia,
celiac disease, and autoimmune hemolytic anemia [6, 7].
Moreover, there is a certain type of anemia that occurs with
Graves’ disease and remains unexplained after excluding all
other possible causes [4, 8]. Because of its clear relation to
GD, and its cure following hyperthyroidism treatment, this
type of anemia may be termed GD anemia [4].
2.1. Graves’ Disease Anemia. In the study by Gianoukakis
et al., GD anemia was found in 22% of GD patients [4].
In GD anemia the mean corpuscular volume (MCV) could
be normal [8] or, probably more commonly, low [4, 9].
Generally the anemia that coexists with GD is observed to
be mild and is commoner with severe disease [5] When
GD anemia is microcytic, iron indices are normal and
hereditary hemoglobinopathies are readily excluded [10].
Anemia may be the sole haematological abnormality, or it
may be combined with thrombocytopenia, or leucopenia;
and occasionally it may be present as a part of a GD-
associated pancytopenia [9, 11, 12]. Erythropoietin levels
are within normal reference ranges [4] and bone marrow, if
examined, is hypercellular or, less commonly, normocellular;
with normal iron stores [9, 13]. The exact pathogenesis
of GD anemia remains unclear [8]; however an eﬀect of
the excess thyroid hormones has been postulated [10]. The
hypercellular marrow may indicate that erythropoiesis is
enhanced due to hyperthyroidism, but in the same time
it is ineﬀective, hence the ﬁnding of anemia with low
MCV [10]. Hematologically, anemia in the presence of
hypercellularmarrowcouldberelatedtoeitherorganseques-
tration such as observed in hypersplenism, an enhanced
removal of circulating red blood cells by an immune or
toxic mechanism, or a hemopoietic stem cell dysfunction
such as myelodysplasia [9]. One or both of the latter 2
mechanisms could be responsible for the GD anemia, with
myelodysplasia being the most widely accepted explanation
[9, 10, 13]. The ﬁnding that thyroid-stimulating hormone
(TSH) receptor antibodies nonspeciﬁcally attach to the
surface of the red blood cells, may suggest an autoimmune
basis for GD anemia [14]. However, the rare occurrence
of GD anemia with hyperthyroid nodular goiter (toxic
multinodular goiter and toxic adenoma) makes the eﬀect of
thyroid hormones on hemopoiesis a more likely explanation
than the autoimmune mechanism [12, 13]. Generally, GD
anemia resembles anemia of chronic disease in many aspects
including red cell morphology, iron status, erythropoietin
levels, and association with markers of inﬂammation [4].
GD anemia was observed to correct promptly with return
to the euthyroid state following hyperthyroidism treatment
[4, 9, 10, 12, 13]. Correction included normalisation of the
haemoglobin concentration and also of the MCV [4, 9, 10].
This improvement was observed regardless of the mode of
therapyofhyperthyroidism,withantithyroiddrugsbeingthe
more commonly used agents in this regard [4, 9, 10, 13].
2.2. Pernicious Anemia. Pernicious anemia is a well-known
form of the autoimmune diseases that may occur in asso-
ciation with GD [6, 7, 15]. In the study by Boelaert et al.,
theprevalenceofperniciousanemiaamongpatientswithGD
was 1.4% compared to 0.13% in the UK general population
[7]. The ﬁnding of megaloblastic anemia (marked macrocy-
tosis with hypersegmanted polymorphonuclear leukocytes)
in the peripheral blood ﬁlm of a GD patient should raise the
suspicion of this association. Anemia may be associated withJournal of Thyroid Research 3
Table 2: Types of Anemia Associated with Graves’ disease (GD).
MCV Iron status# Prevalence in GD
patients
Response to GD
treatment
GD Anemia Low or normal Normal or high 22% Y
Pernicious Anemia High Normal 1.4% N
Iron deﬁciency Anemia of Celiac Disease Low Low 0.9% N
Autoimmune Hemolytic Anemia Normal or high Normal Only single case reports Y∗
Y: Yes; N: No, mean corpuscular volume, #serum iron, serum ferritin, ±bone marrow iron stores, ∗may respond to thionamide drug therapy alone.
leukopenia or thrombocytopenia; or it could form a part of
the pancytopenia of pernicious anemia [16]. The diagnostic
workup is a straight forward one and includes checking
serum vitamin B12 concentration, red cell or serum folate
concentration (to rule out folate deﬁciency), anti-intrinsic
factorantibodygastricparietalcellantibodyandtheSchilling
test.
2.3. Iron Deﬁciency Anemia due to Celiac Disease. In general,
the major cause of iron deﬁciency anemia (microcytic
anemia with a low iron status) is blood loss, either overt
or occult [17]. Lack of evidence of blood loss, or the
refractoriness to treatment with oral iron may lead to the
suspicion of celiac disease. In GD patients, the presence
of an iron deﬁciency anemia may indicate an associated
celiac disease, but of course it does not mean omitting
blood loss as a common possible cause. In the study by
Boelaert et al., the prevalence of celiac disease was 0.9%
in GD patients compared to 0.047% in the general UK
population [7]. Review of the literature also showed that
asymptomatic cases of celiac disease were detected when
patients with autoimmune thyroid disease (including GD)
were screened by autoantibody testing and duodenal biopsy
[18]. However, Sattar et al. stated that screening for celiac
diseaseinpatientswithautoimmunethyroiddiseasemaynot
be justiﬁed without comorbidities or symptoms [19]. When
GD and celiac disease co-exist, it is not clear whether the
treatment of one of them aﬀects the course of the other, but
it is interesting to mention that treatment with a gluten-free
diet has been associated with improvement in the coexistent
Hashimoto’s hypothyroidism, with reduction of the required
thyroxine doses an eﬀect probably related to enhanced drug
absorption [18].
2.4.AutoimmuneHaemolyticAnemia. TheassociationofGD
with autoimmune haemolytic anemia has been described
in single case reports in the English and non-English
literatures [20–23]. It appears that autoimmune haemolytic
anemia is much less commonly found in association with
GD when compared with immune thrombocytopenia and
pernicious anemia [24]. In some of the case reports,
autoimmune haemolytic anemia was present as a part
of Evans’ syndrome (autoimmune haemolytic anemia and
idiopathic thrombocytopenic purpura) in association with
GD [25, 26]. In the study by Rajic et al., on 362 subjects
with autoimmune haematological disorders, there was no
evidence of simultaneous autoimmune thyroid disease in the
subgroup of patients with autoimmune haemolytic anemia
[24]. Ikeda et al. reported a case of Evans’ syndrome in a
patient with GD that was not hyperthyroid after treatment
withradioiodine,andsuggestedthatanunderlyingimmuno-
logical mechanism could be responsible for the association
[25]. In this regard it was very interesting to get an eﬀective
control of hemolysis with the use of an antithyroid drug
alone (namely, propylthiouracil) that was observed in a case
of autoimmune haemolytic anemia [20], and in another one
with Evan’s syndrome [26]. This ﬁnding might be related to
the earlier observation that microsomal antibodies and TSH
receptor antibodies decreased in parallel, while patients with
GD were taking carbimazole, whereas no signiﬁcant changes
were observed during treatment with placebo or propranolol
[27]. The changes in autoantibody levels during carbimazole
treatment were independent of changes in serum thyroxine
and could have been due to a direct eﬀect of the drug on
autoantibody synthesis [27].
3.Vomiting
Vomiting is one of the most common symptoms of gastroin-
testinal disease. Patients with GD may present mainly with
gastrointestinal symptoms that include diarrhea, frequent
defecation,dyspepsia,nausea,vomiting,andabdominalpain
[28]. A special clinical situation arises when a thyrotoxic
patient, who lacks the typical unique features of hyper-
thyroidism, presents with severe and persistent vomiting.
In one of the earliest reports, Rosenthal et al. described
7 patients with thyrotoxic vomiting with a delay in the
detection of hyperthyroidism of 8 & 17 months in two of the
cases [29]. Lack of awareness about the association between
vomiting and hyperthyroidism may lead to a more marked
delay in the diagnosis; that was 7 years in one case report
[30]. In a review of 25 newly diagnosed thyrotoxicosis cases
44% of subjects were complaining of vomiting [31]. The
mechanism by which vomiting develops in hyperthyroid
patients remains uncertain [32]. Researchers have docu-
mented increased levels of estrogens in patients of both sexes
with thyrotoxicosis [32] .E s t r o g e n sm a ya c ta sa ne m e t i c
agent with individual variation in susceptibility between
patients [32]. Another postulated mechanism is through
an increase in beta adrenergic activity due to an increased
numberofbetaadrenergicreceptorsinhyperthyroidpatients
[32]. This mechanism has been concluded from the ﬁnding
of increased adrenergic activity in hyperthyroidism [33],
and from the observation that starting treatment with4 Journal of Thyroid Research
beta blockers ameliorates the vomiting in some cases [32].
However, such an explanation may be debated, as vomiting
is more likely to be linked to hypo-, rather than hyper-
adrenalism. In addition, the beneﬁcial eﬀect of beta blockers
could be due to the reduced thyroid hormone activity
(reduced T3 concentration) and not due to a decrease in
beta adrenergic activity. Another possible mechanism is
through the eﬀect of excess thyroid hormones on gastric
motility. Thyroid hormones are thought to decrease gastric
emptyingsecondarytoamalfunctionofthepyloricsphincter
[32]. In a study on 23 patients with hyperthyroidism, 50%
had delayed gastric emptying [34]. In another study, a
slight but a statistically signiﬁcant increase in the rate of
gastric emptying occurred in patients after restoration of
euthyroidism as compared with healthy control subjects
[35]. In almost all reports, thyrotoxic vomiting showed an
excellent improvement either within several days after the
initiation of antithyroid treatment, or in temporal relation
with the return to the euthyroid state [29, 30, 32].
3.1. Hyperthyroidism with Vomiting in Pregnancy. Vomiting
is common in pregnancy and pregnant women are fre-
quently checked for thyroid disorders [36, 37]. Hyperemesis
gravidarum (HG) is known to be associated with mild
transient hyperthyroidism probably due to the thyroid
stimulating eﬀect of human chorionic gondotropin [36–
39]. On the other hand, frank hyperthyroidism is not
infrequently discovered for the ﬁrst time during pregnancy
with GD being the most common cause [36, 40, 41].
Moreover,hyperthyroidismoccursinpregnancywithclinical
presentation similar to HG and pregnancy itself [36, 41].
A common, challenging scenario develops when a preg-
nant lady gets severe vomiting together with a biochemical
evidence of hyperthyroidism. Here she could be having
either transient hyperthyroidism that is associated with HG,
or overt hyperthyroidism that manifests with vomiting. It
is important to diﬀerentiate between the two conditions
(Table 3) because transient hyperthyroidism with HG is
usually mild, self-limited, and requires no treatment [36,
37]; while frank hyperthyroidism (due to GD in 90%
of cases) confers high maternal and fetal morbidity and
mortality, and needs to be early detected and treated [36,
40,41].Thepresenceofmarkedtachycardia,tremors,muscle
weakness, and ophthalmopathy make the diagnosis of frank
hyperthyroidism more likely (Table 3). Goiter especially if
associated with a thyroid bruit may point to GD, but
one should bear in mind that the thyroid gland may
physiologically enlarge during normal pregnancy [41]. The
presence of severe vomiting makes HG the likely diagnosis
only with the exception of the unusual situation when
vomiting is the main presenting symptom of thyrotoxicosis.
Biochemically, transient hyperthyroidism of HG usually
shows a picture of subclinical hyperthyroidism (Low TSH
and normal free T4). The diagnosis of overt hyperthyroidism
in pregnant women should be based primarily on a serum
TSH value <0.01mU/L and also a high serum-free T4
value [42]. Free T3 measurements may be useful in women
with signiﬁcantly suppressed serum TSH concentrations and
normal or minimally elevated free T4 values [42]. Thyroid
Table 3: Comparison between Graves’ disease hyperthyroidism
(GD) and Transient hyperthyroidism of hyperemesis Gravidarum
(THHG).
GD THHG
Hyperthyroidism
symptoms1 YN
Ophthalmopathy Y N
Goiter Y2 N3
Signiﬁcant weight
loss YN 4
Severe vomiting N5 Y
TSH Low (usually
<0.01mU/L)
Low (usually not
<0.01mU/L)
free T4 High (signiﬁcant rise) Normal (or mild rise)
Free T3 High Normal
Persistence >1st
trimester YN
Treatment required Y N
Y: Yes; N: No, 1tremors, marked tachycardia, muscle weakness. 2especially
with a bruit. 3Thyroid gland may enlarge during normal pregnancy. 4may
be 5% or more in severe cases of HG. 5Rarely severe vomiting is a
hyperthyroidism feature.
peroxidase antibodies are markers of autoimmune thyroid
disease in general and will not diﬀerentiate as they are
found in a considerable percentage of pregnant women. TSH
receptor antibodies may help to indicate that GD is the cause
of the overt hyperthyroidism. Finally, if the clinical and/or
the biochemical hyperthyroidism persist beyond the ﬁrst
trimester, causes of hyperthyroidism other than HG should
be actively sought, putting in mind that some 10% of women
with HG may continue to have symptoms throughout
pregnancy [40].
4.Jaundice
The spectrum of liver aﬀection in GD extends from asymp-
tomatic biochemical abnormality to frank hepatitis [3, 43].
In the vast majority of cases it is only the biochemical
abnormality that attracts the physician rather than the
clinically obvious liver disease [3, 43, 44]. Liver function
derangement in hyperthyroid patients can be mainly sub-
divided into either transaminases elevations (hepatocellular
pattern), or intrahepatic cholestasis [3, 43, 45]. In a study by
G¨ urlek et al., at least one liver function test abnormality was
found in 60.5% of hyperthyroid patients [44]. Elevations of
alkalinephosphatase,alanineaminotransferase,andgamma-
glutamyl transpeptidase levels were observed in 44%, 23%,
and 14% of the patients, respectively [44]. The mechanism
of hepatic injury appears to be relative hypoxia in the
perivenular regions, due to an increase in hepatic oxygen
demand without an appropriate increase in hepatic blood
ﬂow [46]. One theory suggests that the liver is damaged
by the systemic eﬀects of excess thyroid hormones [47].
The hypermetabolic state makes the liver more susceptible
to injury, and, in addition, thyroid hormones might also
have a direct toxic eﬀect on hepatic tissue [47]. In almostJournal of Thyroid Research 5
all the reported cases, the relation of the intrahepatic
cholestasis to hyperthyroidism was documented when the
jaundice has resolved with hyperthyroidism treatment, and
after excluding all other possible causes of cholestasis [45–
47]. Histologically, there are mild lobular inﬂammatory
cellular inﬁltrates in addition to centrilobular intrahepatic
cholestasis [46]. In a case series analysis by Fong et al. the
liver histology changes due to hyperthyroidism were not
characteristic and nonspeciﬁc [48].
Jaundice due to intrahepatic cholestasis may be a promi-
nent symptom in GD patients, and very occasionally it is
the presenting manifestation of thyrotoxicosis [44, 48]. Very
high-serum bilirubin levels (up to 581μmol/L) were occa-
sionally noted in patients with hyperthyroidism [45, 47, 48].
The relation of jaundice to GD (or hyperthyroidism in
general) can be presented in three clinical scenarios. GD may
be the underlying cause of jaundice that develops in a pre-
viously healthy subject [47, 49]. The presentation of GD for
the ﬁrst time with jaundice may lead to unnecessary investi-
gationsandadelayinmanagement[47].Itisprudenttolook
carefully for clinical stigmata of thyroid dysfunction, and to
considercheckingthyroidhormonelevelswhileinvestigating
patientswithjaundiceofunknowncause.Thesecondclinical
scenario develops when a patient with a preexisting chronic
liver disease gets deterioration of his liver function tests with
deep jaundice. Numerous possibilities are usually considered
in this situation including a complicating hepatocellular
carcinoma, viral reactivation or superinfection, sepsis, and
drug side eﬀects. In this setting, hyperthyroidism should not
be omitted as a possible cause. Hegazi et al. reported a case
of deep jaundice caused by hyperthyroidism due to a toxic
adenoma in a patient with hepatitis B cirrhosis, with return
of serum bilirubin to baseline level after treatment with
radio-iodine [45]. Thompson et al. reported a patient with
primary biliary cirrhosis who had dramatic deterioration
of liver functions with jaundice due to the development
of GD [50]. The patient’s jaundice entirely reversed with
treatment of the hyperthyroidism [50]. Thirdly, when a
GD patient develops jaundice, a list of possible causes
should be considered. These include, an unrelated biliary or
hepatic disease [48, 51], an autoimmune liver disease that
is known to be associated with GD [46], hepatic congestion
due to concomitant congestive cardiac failure [48], hepatic
manifestations of hyperthyroidism [47, 49], and hepatotoxic
side eﬀects of antithyroid drugs [52]. In the analysis made
by Fong et al., severe liver test abnormalities, including deep
jaundice occurred in patients with hyperthyroidism alone
and with hyperthyroidism with congestive cardiac failure
[48]. Drug-induced hepatotoxicity should be considered in
those who present with hepatic dysfunction after initiation
of thionamide therapy [46, 53].
Treatment of a hyperthyroid patient with jaundice needs
to be considered and therefore, it will be discussed here.
Review of the literature showed that treatment options
other than thionamide drugs might have been preferably
used in cases of jaundice and hyperthyroidism. In many
of the cases the mode of antithyroid therapy was radio-
iodine [45, 54], or thyroidectomy [51, 55]. Antithyroid
drugs have hepatotoxic side eﬀects in 0.5% of cases with
methimazole and carbimazole mainly producing cholestasis,
and propylthiouracil mainly causing hepatocellular damage
[52]. These side eﬀects are idiosyncratic rather than dose
related [46]. Methimazole therapy may deteriorate a GD-
related cholestatic jaundice [53]. However, it has been
reported that carbimazole and methimazole were success-
fully used in restoring euthyroidism as well as ameliorating
the hyperthyroidism-related jaundice [47, 56].
In the absence of another evidence of liver disease,
and when jaundice is purely due to the hyperthyroidism,
thionamide drugs may be used with monitoring of serum
bilirubin and liver function tests. In patients with acute or
chronic liver disease who develop GD that aggravates their
jaundice, the small probability of hepatotoxic side eﬀects of
thionamide drugsmaycarrytherisk ofinducing fulminating
hepatic failure [51], so that alternative GD treatment options
are preferred.
5.Right Heart Failure
Thyroid hormone eﬀects on the cardiovascular system
include increased resting heart rate, left ventricular con-
tractility, blood volume, and decreased systemic vascular
resistance [57, 58]. Cardiac contractility is enhanced and
cardiac output may be increased by 50% to-300% over
that of normal subjects [57, 58]. The well-recognized
cardiovascular manifestations of hyperthyroidism include
palpitations, tachycardia, exercise intolerance, dyspnea on
exertion, widened pulse pressure, and atrial ﬁbrillation [57,
58]. In spite of the increased cardiac output and contractility,
the left ventricular failure that may occur in severe and
chronic cases of hyperthyroidism could be explained by
a tachycardia-related left ventricular dysfunction, and/or a
thyrotoxic cardiomyopathy [57, 58]. The higher prevalence
of hyperthyroid heart failure in older age groups signiﬁes
the contribution of other cardiovascular comorbidities that
include hypertension and coronary artery disease [57].
In addition to the well-known presentations, a variety of
unusual cardiovascular manifestations are increasingly being
reported in association with hyperthyroidism. These include
pulmonary arterial hypertension (PH) [59, 60], right heart
failure [61, 62], myocardial infarction [63], and heart block
[64]. Clinically, isolated right-sided heart failure may be the
presenting feature of GD.
In an echocardiographic study by Marvisi et al., mild
PH was found in 43% of the 114 hyperthyroid patients
and in none of the healthy control group [59]. In another
study by Merc´ e et al., there was a high prevalence of
PH in hyperthyroid patients [60]. Additional studies [65],
case series [66], and case reports [61] have shown similar
ﬁndings. The pathophysiologic link between thyroid dis-
ease and PH remains unclear [67]. Possible explanations
include immune-mediated endothelial damage or dysfunc-
tion, increased cardiac output resulting in endothelial injury,
andincreasedmetabolismofintrinsicpulmonaryvasodilator
substances [60]. Review of the literature reveals some
support for the immune-mediated mechanism [68, 69]. In
a review by Biondi and kahaly, PH was more linked to GD
than to other causes of hyperthyroidism [68]; and in a study6 Journal of Thyroid Research
by Chu et al., there was a high prevalence of autoimmune
thyroid disease in patients with PH [69]. However, in a
study by Armigliato et al., the immune mechanism has been
questioned because 52% of hyperthyroid subjects with PH
did not have evidence of autoimmune thyroid disease [70].
Also in the study by Merc´ e et al., pulmonary hypertension
did not correlate with the cause of hyperthyroidism [60].
Furthermore, Marvisi et al. found no statistical diﬀerence
in thyroid antibody levels between the hyperthyroid study
group and the euthyroid control group and stated that PH
could be due to a direct inﬂuence of thyroid hormones
on pulmonary vasculature [59]. We tend to believe that an
eﬀect of excess thyroid hormones may be responsible for the
development of PH, especially with the ﬁnding of PH also in
patients with hyperthyroid nodular goiter.
In spite of the observation that PH was mild in most
of the studied hyperthyroid patients [58], cases of severe
PH leading to right-sided heart failure are increasingly being
recognized[71].GDoccasionallypresentswithfrankisolated
right heart failure due to the severe PH [61, 72, 73]. All
other possible causes of right ventricular failure including
left-sided systolic and/or diastolic dysfunctions have been
excluded in reported cases [61]. PH as well as right heart
failure showed improvement after the treatment of the con-
comitanthyperthyroidism[58,61,71,73].Itmaytakeseveral
months for the pulmonary artery pressure to normalize
following the initiation of antithyroid treatment [61, 66].
In one case report, the severe pulmonary hypertension has
dropped to a near-normal value, only after 14 months from
initiation of carbimazole therapy, in spite of a long period of
clinical and biochemical euthyroidism [61].
6. Conclusions andRecommendations
The unusual manifestations of GD are diverse and aﬀect
various body systems. They include hematological, car-
diovascular, gastrointestinal, hepatic, and dermatological
manifestations (Table 1). Reports of other less frequent
or rare presentations like venous thromboembolism [74]
and cerebral vasculitis [75] may need further support and
documentation. One or more of the unusual manifestations
may be the main presenting feature of GD. Awareness about
the relation of these presentations to GD or hyperthyroidism
is essential to avoid wrong diagnosis and unnecessary
investigations.
The mechanism remains uncertain in the majority of the
atypical manifestations. However, a good response to hyper-
thyroidism treatment is almost guaranteed. The response to
hyperthyroidism treatment is either rapid or quite delayed.
In the case of vomiting the response occurs within days,
however, in the case of right heart failure the improvement
occurs within several months from starting the treatment.
The excellent recovery that occurs in response to the
restorationofeuthyroidismmakestheeﬀectofexcessthyroid
hormones the likely underlying mechanism in most of the
cases. With the exception of the autoimmune conditions
that are associated with GD, the occurrence of the atypical
manifestations also in patients with hyperthyroid nodular
goiter stands against an autoimmune basis of pathogenesis.
Such atypical presentations appear to aﬀect signiﬁcant
percentages of GD patients; however, most of the studies
conducted in this respect were small. For instance, vomiting
was a symptom in 44% of 25 thyrotoxic patients [31], and
alkaline phosphatase was raised in 44% of 43 hyperthy-
roid patients [44]. Larger studies to further evaluate the
prevalence of each of the atypical features in GD patients
are needed to conﬁrm that some of these ﬁndings are not
unusual, but are rather under-recognized. The widespread
hyperthyroidism manifestations that inﬂuence all body sys-
tems make us believe that the thyroid hormone eﬀects on
various body tissues are not yet fully unveiled.
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